A molecular system for viral load testing of the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) provides laboratories with greater throughput and less hands-on time, maximizing productivity to meet the needs of the clinical laboratory.

The Versant 440 molecular system uses branched-DNA technology (bDNA), which simplifies testing by eliminating nucleic acid extraction and removing the risk of cross-contamination. The Versant 440 delivers molecular assays for HIV and HCV. Both the Versant HIV-1 RNA and HCV RNA 3.0 assays demonstrate excellent precision across the entire reporting range, and a high level of reproducibility that allows viral load changes to be distinguished accurately, facilitating patient management. A viral load platform designed for flexible walkaway automation, the system streamlines workflow by integrating bar-code data entry, automated reagent processing, detection, downloadable patient worklist, and results through a laboratory information system (LIS) interface software.

Siemens Medical Solutions Diagnostics (Tarrytown, NY, USA) announced that its Versant 440 molecular system has been approved for marketing in Canada. Versant 440 is CE-marked in Europe for use with the Versant HIV-1 RNA, HCV RNA, and HBV DNA 3.0 assays (bDNA).

Siemens provides innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical, and financial outcomes. Recent acquisitions in the area of in-vitro diagnostics--such as Diagnostic Products Corp. and Bayer Diagnostics--mark a significant milestone for Siemens.

http://www.gzjiayumed.com/en/index.asp